<p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）在一份週五發佈給客户和投資者的研究報告中，銀行美林的股票研究人員將其目標價從 17.00 美元上調至 26.00 美元，Benzinga 報道。該券商目前對該股票給予 “中性” 評級。銀行美林的目標價意味着該股票相較於之前收盤價有 0.68% 的潛在上漲空間。</p>
<ul>
<li>從落後者到領軍者：小型股正在崛起</li>
</ul>
<p>其他研究分析師最近也對該股票發佈了研究報告。Weiss Ratings 在 10 月 8 日的報告中重申了對 Arcus Biosciences 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 29 日的研究報告中將 Arcus Biosciences 的目標價從 24.00 美元上調至 28.00 美元，並給予該公司 “買入” 評級。高盛集團在 10 月 30 日的研究報告中將 Arcus Biosciences 的目標價從 14.00 美元上調至 16.00 美元，並給予該公司 “中性” 評級。Truist Financial 在 10 月 7 日的報告中重新發布了 “買入” 評級，並將 Arcus Biosciences 的目標價從 32.00 美元上調至 39.00 美元。最後，富國銀行在 10 月 20 日的報告中將 Arcus Biosciences 的目標價從 25.00 美元上調至 29.00 美元，並給予該股票 “超配” 評級。七位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Arcus Biosciences 的共識評級為 “適度買入”，共識目標價為 29.44 美元。</p>
<p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<p><strong>獲取我們對 RCUS 的最新分析</strong></p>
<h2>Arcus Biosciences 股票表現</h2>
<ul>
<li>MarketBeat 週迴顧 – 7/10 - 7/14</li>
</ul>
<p>在週五的交易中，紐約證券交易所 RCUS 的股票上漲了 0.27 美元，達到了 25.83 美元。該股票的交易量為 362,857 股，而其平均交易量為 1,121,739 股。該公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該股票的市值為 27.9 億美元，市盈率為-7.50，貝塔值為 0.90。Arcus Biosciences 的 52 周低點為 6.50 美元，52 周高點為 26.32 美元。該公司的 50 日移動平均線為 17.67 美元，200 日移動平均線為 12.43 美元。</p>
<p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）最近在 10 月 28 日發佈了季度財報。該公司報告本季度每股收益為（1.27 美元），超出市場共識預期的（1.33 美元）0.06 美元。該業務本季度的收入為 2600 萬美元，而市場共識預期為 1989 萬美元。Arcus Biosciences 的淨利潤率為-136.40%，股本回報率為-68.17%。與去年同期相比，該公司的收入下降了 45.8%。在去年同期，該公司每股收益為（1.00 美元）。分析師預測 Arcus Biosciences 在本財年的每股收益將為-3.15 美元。</p>
<h2>內部活動</h2>
<ul>
<li>吉利德通過投資 AlloVir 和 Arcus 擴大生物技術足跡</li>
</ul>
<p>在其他新聞中，首席財務官 Robert C. Goeltz II 在 10 月 28 日的交易中出售了 5000 股 Arcus Biosciences 的股票。股票以平均價格 20.00 美元出售，總交易額為 100,000.00 美元。交易完成後，首席財務官直接持有該公司 92,138 股股票，價值約為 1,842,760 美元。此交易代表其持股比例減少了 5.15%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席會計官 Alexander Azoy 在 9 月 29 日的交易中出售了 2831 股該公司的股票。股票以平均價格 13.00 美元出售，總價值為 36,803.00 美元。交易完成後，首席會計官直接持有該公司 27,363 股股票，價值約為 355,719 美元。此交易代表其持股比例減少了 9.38%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士共出售了 210,875 股公司股票，價值 4,017,263 美元。當前 9.60% 的股票由公司內部人士持有。</p>
<h2>對 Arcus Biosciences 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 現在擁有該公司 2,748 股股票，價值 37,000 美元，此前在該期間內又購買了 1,021 股。SBI Securities Co. Ltd.在第三季度將其在 Arcus Biosciences 的持股增加了 13,547.6%。SBI Securities Co. Ltd.現在擁有該公司 2,866 股股票，價值 39,000 美元，此前在上個季度又購買了 2,845 股。CWM LLC 在第二季度將其在 Arcus Biosciences 的持股增加了 233.6%。CWM LLC 現在擁有該公司 5,441 股股票，價值 44,000 美元，此前在該期間內又購買了 3,810 股。Ameritas Investment Partners Inc.在第二季度將其在 Arcus Biosciences 的持股增加了 34.3%。Ameritas Investment Partners Inc.現在擁有該公司 7,038 股股票，價值 57,000 美元，此前在上個季度又購買了 1,796 股。最後，PNC Financial Services Group Inc.在第二季度將其在 Arcus Biosciences 的持股增加了 440.3%。PNC Financial Services Group Inc.現在擁有該公司 7,597 股股票，價值 62,000 美元，此前在上個季度又購買了 6,191 股。92.89% 的股票由機構投資者持有。</p>
<h2>關於 Arcus Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Arcus Biosciences, Inc.是一家臨牀階段的生物製藥公司，專注於在美國開發和商業化癌症療法。該公司的產品管線包括 Domvanalimab，一種抗 TIGIT 抗體，目前正在進行第二期和第三期臨牀試驗；以及 AB308，一種正在研究的抗 TIGIT 單克隆抗體，目前處於 1b 期臨牀試驗，旨在研究晚期實體瘤和血液惡性腫瘤患者。</p>
<h2>另見</h2>
<ul>
<li>五隻我們認為比 Arcus Biosciences 更好的股票</li>
<li>如何尋找被低估的股票</li>
<li>加倉 Fiserv 的兩個理由，遠離它的一個理由</li>
<li>技術股解析：關於科技你需要知道的</li>
<li>購買三隻股票以迎接 AI 基礎設施的演變</li>
<li>恒生指數是什麼？</li>
<li>Semtech 的數據中心芯片如何推動 AI 熱潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Arcus Biosciences 嗎？</h2>
<p>在考慮 Arcus Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Arcus Biosciences 並不在名單上。</p>
<p>儘管 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RCUS

<p>美國銀行將 Arcus Biosciences 的目標價格從 17.00 美元上調至 26.00 美元，表示潛在上漲幅度為 0.68%。該股票的共識評級為 “適度買入”，目標價格為 29.44 美元。近期注意到內部人士的銷售和對沖基金活動，內部人士持有該股票的 9.60%</p>

<p>Arcus Biosciences (NYSE:RCUS - Get Free Report) had its price target hoisted by equities researchers at Bank of America from $17.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a &#34;neutral&#34; rating on the stock. Bank of America's target price would indicate a potential upside of 0.68% from the stock's previous close.</p>
<div class="lb-trans"><p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）在一份週五發佈給客户和投資者的研究報告中，銀行美林的股票研究人員將其目標價從 17.00 美元上調至 26.00 美元，Benzinga 報道。該券商目前對該股票給予 “中性” 評級。銀行美林的目標價意味着該股票相較於之前收盤價有 0.68% 的潛在上漲空間。</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>從落後者到領軍者：小型股正在崛起</li>
</ul>
</div><p>Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. HC Wainwright lifted their price target on Arcus Biosciences from $24.00 to $28.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 30th. Truist Financial reissued a &#34;buy&#34; rating and issued a $39.00 price target (up previously from $32.00) on shares of Arcus Biosciences in a report on Tuesday, October 7th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Arcus Biosciences has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $29.44.</p>
<div class="lb-trans"><p>其他研究分析師最近也對該股票發佈了研究報告。Weiss Ratings 在 10 月 8 日的報告中重申了對 Arcus Biosciences 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 29 日的研究報告中將 Arcus Biosciences 的目標價從 24.00 美元上調至 28.00 美元，並給予該公司 “買入” 評級。高盛集團在 10 月 30 日的研究報告中將 Arcus Biosciences 的目標價從 14.00 美元上調至 16.00 美元，並給予該公司 “中性” 評級。Truist Financial 在 10 月 7 日的報告中重新發布了 “買入” 評級，並將 Arcus Biosciences 的目標價從 32.00 美元上調至 39.00 美元。最後，富國銀行在 10 月 20 日的報告中將 Arcus Biosciences 的目標價從 25.00 美元上調至 29.00 美元，並給予該股票 “超配” 評級。七位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Arcus Biosciences 的共識評級為 “適度買入”，共識目標價為 29.44 美元。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Analysis on RCUS</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 RCUS 的最新分析</strong></p>
</div><h2>Arcus Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股票表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 7/10 - 7/14</li>
</ul>
</div><p>Shares of NYSE RCUS traded up $0.27 during trading on Friday, reaching $25.83. 362,857 shares of the stock traded hands, compared to its average volume of 1,121,739. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The stock has a market capitalization of $2.79 billion, a P/E ratio of -7.50 and a beta of 0.90. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $26.32. The company has a 50-day moving average of $17.67 and a 200-day moving average of $12.43.</p>
<div class="lb-trans"><p>在週五的交易中，紐約證券交易所 RCUS 的股票上漲了 0.27 美元，達到了 25.83 美元。該股票的交易量為 362,857 股，而其平均交易量為 1,121,739 股。該公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該股票的市值為 27.9 億美元，市盈率為-7.50，貝塔值為 0.90。Arcus Biosciences 的 52 周低點為 6.50 美元，52 周高點為 26.32 美元。該公司的 50 日移動平均線為 17.67 美元，200 日移動平均線為 12.43 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company's revenue was down 45.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.00) earnings per share. Analysts forecast that Arcus Biosciences will post -3.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）最近在 10 月 28 日發佈了季度財報。該公司報告本季度每股收益為（1.27 美元），超出市場共識預期的（1.33 美元）0.06 美元。該業務本季度的收入為 2600 萬美元，而市場共識預期為 1989 萬美元。Arcus Biosciences 的淨利潤率為-136.40%，股本回報率為-68.17%。與去年同期相比，該公司的收入下降了 45.8%。在去年同期，該公司每股收益為（1.00 美元）。分析師預測 Arcus Biosciences 在本財年的每股收益將為-3.15 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通過投資 AlloVir 和 Arcus 擴大生物技術足跡</li>
</ul>
</div><p>In other news, CFO Robert C. Goeltz II sold 5,000 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the chief financial officer directly owned 92,138 shares in the company, valued at approximately $1,842,760. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CAO Alexander Azoy sold 2,831 shares of the firm's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $13.00, for a total value of $36,803.00. Following the transaction, the chief accounting officer directly owned 27,363 shares of the company's stock, valued at approximately $355,719. This trade represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 210,875 shares of company stock worth $4,017,263. 9.60% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Robert C. Goeltz II 在 10 月 28 日的交易中出售了 5000 股 Arcus Biosciences 的股票。股票以平均價格 20.00 美元出售，總交易額為 100,000.00 美元。交易完成後，首席財務官直接持有該公司 92,138 股股票，價值約為 1,842,760 美元。此交易代表其持股比例減少了 5.15%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席會計官 Alexander Azoy 在 9 月 29 日的交易中出售了 2831 股該公司的股票。股票以平均價格 13.00 美元出售，總價值為 36,803.00 美元。交易完成後，首席會計官直接持有該公司 27,363 股股票，價值約為 355,719 美元。此交易代表其持股比例減少了 9.38%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士共出售了 210,875 股公司股票，價值 4,017,263 美元。當前 9.60% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Arcus Biosciences</h2>
<div class="lb-trans"><h2>對 Arcus Biosciences 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in shares of Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after purchasing an additional 1,021 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company's stock worth $39,000 after purchasing an additional 2,845 shares in the last quarter. CWM LLC raised its stake in Arcus Biosciences by 233.6% during the 2nd quarter. CWM LLC now owns 5,441 shares of the company's stock valued at $44,000 after purchasing an additional 3,810 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock worth $57,000 after purchasing an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Arcus Biosciences by 440.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company's stock valued at $62,000 after buying an additional 6,191 shares in the last quarter. 92.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 現在擁有該公司 2,748 股股票，價值 37,000 美元，此前在該期間內又購買了 1,021 股。SBI Securities Co. Ltd.在第三季度將其在 Arcus Biosciences 的持股增加了 13,547.6%。SBI Securities Co. Ltd.現在擁有該公司 2,866 股股票，價值 39,000 美元，此前在上個季度又購買了 2,845 股。CWM LLC 在第二季度將其在 Arcus Biosciences 的持股增加了 233.6%。CWM LLC 現在擁有該公司 5,441 股股票，價值 44,000 美元，此前在該期間內又購買了 3,810 股。Ameritas Investment Partners Inc.在第二季度將其在 Arcus Biosciences 的持股增加了 34.3%。Ameritas Investment Partners Inc.現在擁有該公司 7,038 股股票，價值 57,000 美元，此前在上個季度又購買了 1,796 股。最後，PNC Financial Services Group Inc.在第二季度將其在 Arcus Biosciences 的持股增加了 440.3%。PNC Financial Services Group Inc.現在擁有該公司 7,597 股股票，價值 62,000 美元，此前在上個季度又購買了 6,191 股。92.89% 的股票由機構投資者持有。</p>
</div><h2>About Arcus Biosciences</h2>
<div class="lb-trans"><h2>關於 Arcus Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家臨牀階段的生物製藥公司，專注於在美國開發和商業化癌症療法。該公司的產品管線包括 Domvanalimab，一種抗 TIGIT 抗體，目前正在進行第二期和第三期臨牀試驗；以及 AB308，一種正在研究的抗 TIGIT 單克隆抗體，目前處於 1b 期臨牀試驗，旨在研究晚期實體瘤和血液惡性腫瘤患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>How to Find Undervalued Stocks</li>
<li>2 Reasons to Load Up on Fiserv, 1 to Stay Away</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>3 Stocks to Buy for the Evolution of AI Infrastructure</li>
<li>What is the Hang Seng index?</li>
<li>How Semtech’s Data Center Chips Are Powering the AI Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Arcus Biosciences 更好的股票</li>
<li>如何尋找被低估的股票</li>
<li>加倉 Fiserv 的兩個理由，遠離它的一個理由</li>
<li>技術股解析：關於科技你需要知道的</li>
<li>購買三隻股票以迎接 AI 基礎設施的演變</li>
<li>恒生指數是什麼？</li>
<li>Semtech 的數據中心芯片如何推動 AI 熱潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=RCUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Arcus Biosciences 嗎？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Arcus Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Arcus Biosciences 並不在名單上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

美國銀行的分析師表示，Arcus Biosciences（NYSE:RCUS）的股價預計將會上漲